1.
Sylvia Herter, Frank Herting, Gunter Muth, Erwin van Puijenbroek, Tilman Schlothauer, Claudia Ferrara, Kevin Brady, Sabine Lang, Marina Bacac, Ekkehard Mössner, Pablo Umana, Christian Klein. GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity. Haematologica 2018;103(2):e78-e81; https://doi.org/10.3324/haematol.2017.178996.